Peptide Comparisons

BPC-157 excels at localized tendon, ligament, and gut healing. TB-500 is better for systemic muscle recovery and widespread inflammation.

Tirzepatide produces greater average weight loss in clinical trials. Semaglutide has a longer post-market safety record. Both are excellent options.

Ipamorelin and CJC-1295 work through complementary mechanisms and are almost always used together rather than as alternatives.

Ozempic and Wegovy both contain Semaglutide. The difference is FDA indication and maximum dose — Wegovy is approved for weight management at higher doses.

Mounjaro and Zepbound both contain Tirzepatide. Mounjaro is approved for Type 2 diabetes; Zepbound for obesity. The active ingredient is identical.

Selank is primarily anxiolytic — it reduces anxiety and improves mood. Semax is primarily a cognitive enhancer — it boosts focus, memory, and BDNF. They are frequently combined.

Epithalon targets cellular aging through telomere maintenance. GHK-Cu addresses visible aging through collagen synthesis and tissue remodeling. They work through complementary mechanisms.

Sermorelin has the strongest clinical evidence and requires a prescription. Ipamorelin is available as a research compound and is typically combined with CJC-1295.

BPC-157 excels at tendon, ligament, and gut healing. GHK-Cu excels at skin, hair, and collagen synthesis. They address different healing targets.

TB-500 provides systemic muscle and tissue repair. GHK-Cu excels at collagen synthesis, skin health, and wound healing.

Tesamorelin is specifically validated for visceral fat reduction and requires a prescription. Ipamorelin provides broader GH benefits including muscle growth and sleep.

Semaglutide is FDA-approved and widely available. Retatrutide is a triple agonist (GLP-1/GIP/glucagon) in Phase III trials showing superior weight loss.

Semaglutide has vastly stronger clinical evidence for weight loss. AOD-9604 is a research compound with limited human data.

CJC-1295 is a GHRH analogue; GHRP-6 is an older GHRP. Ipamorelin has largely replaced GHRP-6 due to its cleaner side effect profile.

PT-141 is FDA-approved for HSDD with strong evidence. Kisspeptin is an emerging research peptide with promising but limited human data.

Semaglutide produces greater weight loss than Liraglutide in head-to-head trials and requires only weekly rather than daily injections.

MOTS-c is a mitochondrial peptide that activates AMPK. NAD+ precursors (NMN, NR) restore NAD+ levels. They work through complementary mechanisms.

Mounjaro (tirzepatide) produces greater average weight loss in clinical trials due to its dual GIP/GLP-1 mechanism. Ozempic (semaglutide) has a longer safety track record and broader insurance coverage.

Ozempic (semaglutide) produces significantly greater weight loss than Saxenda (liraglutide) and requires only once-weekly dosing vs daily. Saxenda has a longer track record in obesity specifically.

Both are highly effective. Mounjaro produces greater average weight loss (~20-22% vs ~15%) but Wegovy has longer obesity-specific approval history. The choice often comes down to insurance and individual response.

Wegovy (semaglutide 2.4mg) produces significantly greater weight loss (~15% vs ~8%) and requires only once-weekly dosing. Saxenda (liraglutide) has a longer obesity-specific track record.

Retatrutide's triple agonism (GIP + GLP-1 + glucagon) produced ~24% weight loss in Phase 2 trials, potentially exceeding tirzepatide. However, retatrutide is not yet FDA approved as of 2025.

Both contain semaglutide but differ in delivery. Ozempic (injectable) achieves higher bioavailability and greater weight loss. Rybelsus (oral) is more convenient but requires strict fasting protocols and produces less weight loss.

Ozempic (semaglutide) produces significantly greater weight loss and HbA1c reduction than Trulicity (dulaglutide) in head-to-head trials. Trulicity remains a reasonable option for patients who cannot tolerate semaglutide.

Ozempic (semaglutide) produces greater HbA1c reduction and weight loss than Victoza (liraglutide) and requires only once-weekly dosing. Victoza has a longer track record and strong cardiovascular outcome data.

Ipamorelin produces cleaner, more selective GH pulses with fewer side effects. Sermorelin mimics the natural GHRH mechanism more closely and has more clinical data. Both are effective; the choice depends on your protocol goals.

CJC-1295 has a dramatically longer half-life (days vs minutes) due to its DAC modification, producing sustained GH elevation. Sermorelin produces more physiological pulsatile GH release. The choice depends on whether you want sustained or pulsatile GH.

GHRP-2 produces stronger GH release than GHRP-6 but also causes greater cortisol and prolactin elevation. GHRP-6 causes more pronounced hunger. Both have been largely superseded by ipamorelin for most protocols.

Ipamorelin is the clear choice for most modern protocols. It produces selective GH release without cortisol or prolactin elevation, and without the pronounced hunger of GHRP-6. GHRP-6 may be preferred when appetite stimulation is desired.

Ipamorelin is preferred for long-term protocols due to its selective GH release and minimal side effects. GHRP-2 may be chosen when maximum GH stimulation is needed short-term, accepting higher cortisol and prolactin.

Hexarelin is the most potent GHRP but causes significant receptor desensitization and cortisol/prolactin elevation. Ipamorelin is less potent but far more suitable for sustained protocols due to its selectivity.

Tesamorelin has FDA approval for HIV-associated lipodystrophy and strong clinical data for visceral fat reduction. Sermorelin is more commonly used off-label for anti-aging and GH optimization with a longer track record in that context.

CJC-1295 with DAC provides sustained GH elevation with 1-2x weekly dosing. Without DAC (Mod GRF 1-29) produces pulsatile GH release requiring daily dosing. The choice depends on whether you want sustained or physiological pulsatile GH.

Sermorelin stimulates the pituitary to produce GH naturally, preserving feedback mechanisms and costing significantly less than synthetic HGH. HGH provides direct GH replacement but bypasses natural regulation and carries higher risks.

Ipamorelin offers a safer, more affordable approach to GH optimization by stimulating natural pulsatile GH release. Synthetic HGH provides direct, predictable GH replacement but at significantly higher cost and risk.

BPC-157 and ipamorelin serve fundamentally different purposes. BPC-157 is a healing and repair peptide; ipamorelin is a GH secretagogue for body composition and anti-aging. They are often combined rather than compared.

Epithalon activates telomerase to extend telomeres; NAD+ precursors restore declining NAD+ levels for sirtuin activation and DNA repair. They target different hallmarks of aging and are frequently combined in comprehensive longevity protocols.

GHK-Cu primarily targets tissue repair, collagen synthesis, and skin anti-aging. NAD+ precursors address cellular energy, DNA repair, and systemic aging. They are complementary rather than competitive.

IV NAD+ provides immediate, high-bioavailability NAD+ restoration but requires clinical administration and is expensive. NMN is a convenient oral precursor with growing clinical evidence. For most people, oral NMN is the practical starting point.

NMN and NR are more direct NAD+ precursors with fewer side effects than niacin. Niacin is the most cost-effective NAD+ booster but causes flushing. For longevity protocols, NMN or NR are generally preferred.

Selank is the clear choice for anxiety reduction due to its GABAergic mechanism. Semax is better for cognitive enhancement and focus. For anxiety specifically, selank is more targeted and better supported by evidence.

Semax has more human clinical data and a longer track record. Dihexa is theoretically more potent for neurogenesis but has minimal human data. Semax is the safer starting point for cognitive enhancement.

PT-141 (bremelanotide) works centrally through melanocortin receptors to enhance sexual desire. Tadalafil works peripherally by increasing blood flow. They address different aspects of sexual function and are often combined.

PT-141 addresses sexual desire through central melanocortin pathways; sildenafil addresses erectile function through peripheral blood flow. They are complementary rather than competing, targeting different aspects of sexual health.

PT-141 was derived from Melanotan II specifically to retain sexual health effects while removing the tanning/pigmentation effects. For sexual health purposes, PT-141 is the more targeted and FDA-approved option.

Both GHK-Cu and retinol stimulate collagen production and reduce signs of aging, but through different mechanisms. Retinol has more extensive clinical evidence; GHK-Cu is better tolerated and has additional wound healing and anti-inflammatory properties.

GHK-Cu actively repairs and remodels skin through collagen synthesis and wound healing. Hyaluronic acid is a humectant that provides hydration and plumping. They serve different purposes and are best used together.

Minoxidil has decades of clinical evidence as the gold standard topical hair loss treatment. GHK-Cu has emerging evidence for hair follicle health and may enhance minoxidil's effects. For established hair loss, minoxidil has stronger evidence.

Minoxidil has far more clinical evidence for hair loss specifically. BPC-157 may support hair follicle health through angiogenesis and anti-inflammatory effects, but is not primarily a hair loss treatment. Minoxidil is the first-line choice.

Thymosin Alpha-1 modulates adaptive immunity through T-cell regulation and has the strongest clinical evidence of any immune peptide. LL-37 is an antimicrobial peptide with innate immune effects. They target different aspects of immune function.

Thymosin Alpha-1 and BPC-157 serve fundamentally different purposes. Thymosin Alpha-1 is an immune modulator; BPC-157 is a tissue healing peptide. The choice depends entirely on whether immune support or tissue repair is the primary goal.

LL-37 and BPC-157 have overlapping applications in wound healing and infection control but through different mechanisms. BPC-157 has more extensive research; LL-37 adds direct antimicrobial activity.

SNAP-8 is an 8-amino acid extension of argireline (6 amino acids) that is claimed to be more potent. Both reduce expression lines by inhibiting SNARE complex formation. Evidence for both is primarily industry-funded.

GHK-Cu and argireline work through completely different mechanisms. GHK-Cu repairs skin structure through collagen synthesis; argireline reduces expression lines by inhibiting muscle contractions. They are complementary.

Orforglipron is a promising oral non-peptide GLP-1 agonist in late-stage trials that does not require fasting like Rybelsus. If approved, it could significantly expand access to GLP-1 therapy. Semaglutide remains the current standard.

Tirzepatide has robust clinical trial data and FDA approval. AOD-9604 has limited human data and failed its FDA approval process. For clinically validated fat loss, tirzepatide is the evidence-based choice.

Oxytocin enhances bonding, trust, and sexual arousal through central mechanisms. Kisspeptin regulates reproductive hormone release (LH, FSH, testosterone). They target different aspects of sexual and reproductive health.

PT-141 activates melanocortin-4 receptors to enhance sexual desire and arousal. Oxytocin enhances bonding, trust, and arousal through different central pathways. Both work centrally and are often combined.

Kisspeptin works upstream by regulating reproductive hormone production (testosterone, LH, FSH). PT-141 works downstream by directly activating brain pathways for sexual desire. They address different root causes of sexual health issues.

DSIP (delta sleep-inducing peptide) directly promotes slow-wave delta sleep. Selank reduces anxiety and stress that can disrupt sleep. For primary sleep disorders, DSIP is more targeted; for anxiety-driven insomnia, selank may be more effective.

DSIP directly promotes delta sleep. Ipamorelin supports sleep quality indirectly through GH pulse stimulation (which naturally peaks during deep sleep). They work through different mechanisms and are often combined.

Cerebrolysin has strong clinical evidence from European trials for stroke recovery and dementia. Dihexa is theoretically more potent for neurogenesis but has minimal human data.

Cerebrolysin has stronger clinical evidence for neuroprotection and recovery from neurological injury. Semax is better suited for cognitive enhancement and daily nootropic use due to its nasal spray delivery and BDNF-upregulating effects.

BPC-157 promotes gut healing through growth factor upregulation and angiogenesis. Glutamine is the primary fuel for intestinal epithelial cells and supports gut barrier integrity. They work through different mechanisms and are often combined.

BPC-157 promotes active gut repair through growth factors and angiogenesis. Zinc carnosine protects the gut lining and has clinical evidence for H. pylori and gastric ulcers. They are complementary rather than competing.

TB-500 and ipamorelin serve different purposes. TB-500 promotes tissue healing, flexibility, and recovery. Ipamorelin stimulates GH release for body composition and anti-aging. They are frequently combined in athlete recovery protocols.

Semaglutide consistently outperforms liraglutide in head-to-head trials for HbA1c reduction and weight loss, with the added convenience of once-weekly dosing. Liraglutide has a longer track record and strong cardiovascular outcome data.

Tirzepatide produces greater average weight loss (~20-22% vs ~15%) due to its dual GIP/GLP-1 mechanism. Semaglutide has a longer track record and more extensive cardiovascular outcome data. Both are excellent first-line options.

BPC-157 promotes active tissue repair through growth factors. NAC is a glutathione precursor with antioxidant and mucolytic effects, particularly relevant for liver health and oxidative stress. They target different aspects of health.

GHK-Cu focuses on tissue repair, collagen synthesis, and skin anti-aging. Epithalon targets telomere biology through telomerase activation. They address different hallmarks of aging and are frequently combined.

MOTS-c and humanin are both mitochondrial-derived peptides but with different primary effects. MOTS-c focuses on metabolic regulation and AMPK activation. Humanin is primarily neuroprotective with anti-apoptotic effects.

Ipamorelin produces pulsatile GH release through injection, preserving natural GH rhythms. MK-677 is an oral GH secretagogue that produces sustained GH elevation but causes more side effects including water retention and increased appetite.

CJC-1295 and GHRP-6 work through complementary mechanisms (GHRH + GHRP) and produce synergistic GH release when combined. As standalone options, CJC-1295 is more commonly used in modern protocols due to its longer half-life.

Tesamorelin has FDA approval and strong clinical evidence for visceral fat reduction. Ipamorelin is better suited for general GH optimization and anti-aging. They work through complementary mechanisms and are often combined.

BPC-157 is the most potent systemic healing peptide for injuries, gut, and inflammation. GHK-Cu excels at skin anti-aging, wound healing, and collagen synthesis. They are complementary rather than competing.